Last reviewed · How we verify
Autologous blood transfusion — Competitive Intelligence Brief
phase 3
Hematology/Transfusion Medicine
Biologic
Live · refreshed every 30 min
Target snapshot
Autologous blood transfusion (Autologous blood transfusion) — Centre Hospitalier Universitaire Vaudois. Autologous blood transfusion returns a patient's own previously collected blood to restore circulating volume and oxygen-carrying capacity.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Autologous blood transfusion TARGET | Autologous blood transfusion | Centre Hospitalier Universitaire Vaudois | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Autologous blood transfusion CI watch — RSS
- Autologous blood transfusion CI watch — Atom
- Autologous blood transfusion CI watch — JSON
- Autologous blood transfusion alone — RSS
Cite this brief
Drug Landscape (2026). Autologous blood transfusion — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-blood-transfusion. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab